



Jazz Pharmaceuticals Exclusive Licensing Agreement with Sumitomo Pharma to Develop and Commercialize DSP-0187

Jazz Pharmaceuticals announced on May 4, 2022 that the company entered into an exclusive licensing agreement with Sumitomo Pharma Co., Ltd. under which Jazz has acquired rights in the United States, Europe and other territories to develop and commercialize Sumitomo Pharma's investigational DSP-0187, now called JZP441, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders.

Orexin agonism is an exciting area of sleep disorder research. As background, Sumitomo Pharma initiated a Phase 1 study trial in Japan of the molecule in November 2021 to evaluate safety, tolerability and pharmacokinetics in healthy volunteers. Jazz is planning to rapidly advance the development of JZP441 based on these clinical findings, and the company will keep the sleep community updated on future clinical trial milestones.

Jazz has a long-standing commitment to developing novel, innovative options for patients living with sleep disorders, and this milestone further supports this commitment. We are steadfast in our commitment to improve the lives of people living with these debilitating sleep disorders and are excited for the potential this molecule has for the future of sleep medicine.

Thank you for your continued partnership and support of people living with sleep disorders.